ZA202004327B - Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability - Google Patents
Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeabilityInfo
- Publication number
- ZA202004327B ZA202004327B ZA2020/04327A ZA202004327A ZA202004327B ZA 202004327 B ZA202004327 B ZA 202004327B ZA 2020/04327 A ZA2020/04327 A ZA 2020/04327A ZA 202004327 A ZA202004327 A ZA 202004327A ZA 202004327 B ZA202004327 B ZA 202004327B
- Authority
- ZA
- South Africa
- Prior art keywords
- intraocular
- medicine
- preventing
- disease associated
- vascular permeability
- Prior art date
Links
- 206010029113 Neovascularisation Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000008728 vascular permeability Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018016911 | 2018-02-02 | ||
| PCT/JP2019/003573 WO2019151470A1 (en) | 2018-02-02 | 2019-02-01 | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202004327B true ZA202004327B (en) | 2022-01-26 |
Family
ID=67479734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/04327A ZA202004327B (en) | 2018-02-02 | 2020-07-14 | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20210113529A1 (en) |
| EP (1) | EP3747471A4 (en) |
| JP (1) | JPWO2019151470A1 (en) |
| KR (1) | KR20200116953A (en) |
| CN (1) | CN111683682A (en) |
| AU (1) | AU2019214265A1 (en) |
| BR (1) | BR112020015567A2 (en) |
| CA (1) | CA3089952A1 (en) |
| IL (1) | IL275603A (en) |
| JO (1) | JOP20200186A1 (en) |
| MA (1) | MA53098A (en) |
| MX (1) | MX2020007948A (en) |
| PH (1) | PH12020551015A1 (en) |
| RU (1) | RU2020128700A (en) |
| SG (1) | SG11202006255UA (en) |
| WO (1) | WO2019151470A1 (en) |
| ZA (1) | ZA202004327B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021148439A1 (en) * | 2020-01-21 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for stimulating cerebrovascular function |
| WO2021163355A1 (en) * | 2020-02-11 | 2021-08-19 | Arena Pharmaceuticals, Inc. | Formulations and methods of treating conditions related to the s1p1 receptor |
| IL298996A (en) * | 2020-06-11 | 2023-02-01 | Univ Columbia | Methods and compositions for preventing and treating myopia with fingolimod, a sphingosine-1-phosphate receptor modulator, and derivatives thereof |
| CN113082031A (en) * | 2021-03-09 | 2021-07-09 | 温州医科大学附属眼视光医院 | Application of dopamine D1 and D2 receptor nonselective agonist in preparation of drugs for treating pathological angiogenesis of eyes |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2529318C (en) * | 2003-06-24 | 2013-09-17 | University Of Connecticut | Methods of inhibiting vascular permeability and apoptosis |
| US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| JP4993407B2 (en) | 2004-08-04 | 2012-08-08 | 大正製薬株式会社 | Triazole derivative |
| GB0504544D0 (en) * | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
| CN101415691B (en) | 2006-02-03 | 2011-12-14 | 大正制药株式会社 | Triazole derivative |
| EP1988081B1 (en) | 2006-02-06 | 2012-10-17 | Taisho Pharmaceutical Co., Ltd | Binding inhibitor of sphingosine-1-phosphate |
| PL2003132T3 (en) | 2006-04-03 | 2014-10-31 | Astellas Pharma Inc | Oxadiazole derivatives as S1P1 agonists |
| US8444970B2 (en) | 2006-10-27 | 2013-05-21 | Lpath, Inc. | Compositions and methods for treating ocular diseases and conditions |
| US20100111963A1 (en) | 2006-11-10 | 2010-05-06 | Genentech, Inc. | Method for treating age-related macular degeneration |
| EP2014653A1 (en) * | 2007-06-15 | 2009-01-14 | Bioprojet | Novel dicarboxylic acid derivatives as S1P1 receptor agonists |
| US8048898B2 (en) | 2007-08-01 | 2011-11-01 | Taisho Pharmaceutical Co., Ltd | Inhibitor of binding of S1P1 |
| PL2354134T3 (en) | 2008-12-05 | 2016-07-29 | Astellas Pharma Inc | 2h-chromene derivatives as stimulators of sphingosine 1-phosphate receptor |
| CN102686574A (en) | 2009-10-23 | 2012-09-19 | 阿勒根公司 | Coumarin compounds as receptor modulators with therapeutic utility |
| NZ599966A (en) | 2009-11-24 | 2014-09-26 | Allergan Inc | Novel compounds as receptor modulators with therapeutic utility |
| US20120301478A1 (en) | 2010-01-14 | 2012-11-29 | Yuichiro Ogura | Pharmaceutical for Preventing or Treating Disorders Accompanied by Ocular Angiogenesis and/or Elevated Ocular Vascular Permeability |
| US8273776B2 (en) | 2010-04-16 | 2012-09-25 | Allergan, Inc | Biphenyl oxadiazole derivatives as sphingosine-1-phosphate receptors modulators |
| WO2012071186A1 (en) | 2010-11-24 | 2012-05-31 | Allergan, Inc. | Modulators of s1p receptors |
| CN103380112A (en) | 2010-11-24 | 2013-10-30 | 阿勒根公司 | Indole derivatives as modulators of S1P receptors |
| WO2012074921A1 (en) | 2010-12-03 | 2012-06-07 | Allergan, Inc. | Alkyne and alkene derivatives as sphingosine 1-phosphate-1 receptor modulators |
| WO2012105610A1 (en) | 2011-02-02 | 2012-08-09 | 公立大学法人名古屋市立大学 | Medicinal agent for prevention or treatment of diseases associated with intraocular neovascularization and/or intraocular vascular hyperpermeability |
| EP2697195A1 (en) | 2011-04-14 | 2014-02-19 | Allergan, Inc. | Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators |
| CA2833545A1 (en) | 2011-04-18 | 2012-10-26 | Allergan, Inc. | Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators |
| US9000016B2 (en) | 2012-11-05 | 2015-04-07 | Allergan, Inc. | 1,3,4-Oxadiazoles-2-thio derivatives as sphingosine-1 phosphate receptors modulators |
| US8735433B1 (en) | 2012-11-14 | 2014-05-27 | Allergan, Inc. | Aryl oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators |
| WO2014130565A1 (en) | 2013-02-20 | 2014-08-28 | Allergan, Inc. | Substituted diaryl azetidine derivatives as sphingosine receptor modulators |
| EP2990055B1 (en) * | 2013-04-26 | 2019-06-05 | Kyoto University | Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it |
| JP2018016911A (en) | 2016-07-28 | 2018-02-01 | 村田機械株式会社 | Analyzer |
-
2019
- 2019-02-01 JO JOP/2020/0186A patent/JOP20200186A1/en unknown
- 2019-02-01 JP JP2019569604A patent/JPWO2019151470A1/en active Pending
- 2019-02-01 CN CN201980010708.6A patent/CN111683682A/en active Pending
- 2019-02-01 CA CA3089952A patent/CA3089952A1/en active Pending
- 2019-02-01 KR KR1020207024569A patent/KR20200116953A/en not_active Application Discontinuation
- 2019-02-01 RU RU2020128700A patent/RU2020128700A/en unknown
- 2019-02-01 AU AU2019214265A patent/AU2019214265A1/en not_active Abandoned
- 2019-02-01 BR BR112020015567-5A patent/BR112020015567A2/en not_active IP Right Cessation
- 2019-02-01 US US16/966,757 patent/US20210113529A1/en not_active Abandoned
- 2019-02-01 EP EP19747229.3A patent/EP3747471A4/en not_active Withdrawn
- 2019-02-01 MA MA053098A patent/MA53098A/en unknown
- 2019-02-01 MX MX2020007948A patent/MX2020007948A/en unknown
- 2019-02-01 WO PCT/JP2019/003573 patent/WO2019151470A1/en unknown
- 2019-02-01 SG SG11202006255UA patent/SG11202006255UA/en unknown
-
2020
- 2020-06-23 IL IL275603A patent/IL275603A/en unknown
- 2020-06-29 PH PH12020551015A patent/PH12020551015A1/en unknown
- 2020-07-14 ZA ZA2020/04327A patent/ZA202004327B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3747471A1 (en) | 2020-12-09 |
| IL275603A (en) | 2020-08-31 |
| MA53098A (en) | 2021-05-12 |
| SG11202006255UA (en) | 2020-07-29 |
| WO2019151470A1 (en) | 2019-08-08 |
| RU2020128700A3 (en) | 2022-03-02 |
| JOP20200186A1 (en) | 2020-07-29 |
| MX2020007948A (en) | 2020-12-10 |
| CN111683682A (en) | 2020-09-18 |
| JPWO2019151470A1 (en) | 2021-02-25 |
| PH12020551015A1 (en) | 2021-09-06 |
| AU2019214265A1 (en) | 2020-07-23 |
| KR20200116953A (en) | 2020-10-13 |
| EP3747471A4 (en) | 2021-10-27 |
| BR112020015567A2 (en) | 2021-02-02 |
| CA3089952A1 (en) | 2019-08-08 |
| US20210113529A1 (en) | 2021-04-22 |
| RU2020128700A (en) | 2022-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004327B (en) | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability | |
| EP3749264C0 (en) | Laser therapy for treatment and prevention of eye diseases | |
| EP3823569C0 (en) | Integrated surgical system for treatment in the irido-corneal angle of the eye | |
| IL268327A (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
| IL281773A (en) | Ophthalmic composition for treatment of dry eye disease | |
| IL277557A (en) | Sap and peptidomimetics for treatment of eye disease | |
| IL284344A (en) | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease | |
| EP3405159A4 (en) | Treatment and prevention of retinal vascular disease by photocoagulation | |
| IL269083A (en) | Methods for preventing and treating heart disease | |
| EP3481411A4 (en) | Treatment for glaucoma and other eye diseases | |
| IL282504A (en) | Ocular formulations for drug-delivery and protection of the anterior segment of the eye | |
| IL289405A (en) | Personalized treatment of ophthalmologic diseases | |
| IL269698B (en) | Methods of preventing or treating ophthalmic diseases | |
| MX2017005522A (en) | Novel treatment of cornea using laminin. | |
| LT3949971T (en) | Use of luteolin-7-o-glucoside or luteolin-7-o-glucuronide in preparation of medicine for eye injuries | |
| EP3691654A4 (en) | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease | |
| SG11202012473UA (en) | Ophthalmic compositions and methods for the treatment of eye disorders | |
| SG11202102411WA (en) | Simulated sclera and simulated eyeball | |
| IL282898A (en) | Ophthalmic compositions and methods for the treatment of skin diseases and eye diseases | |
| IL280588A (en) | Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases | |
| IL279164A (en) | Corneal implant | |
| HUE061286T2 (en) | Nutraceutical ophthalmic composition for treating diseases of the retina with neovascular component | |
| GB201914516D0 (en) | Treatment of eye disease | |
| SG11202005278PA (en) | Compounds for treating eye diseases and methods thereof | |
| IL291522A (en) | Anti-nrp1a antibodies and their uses for treating eye or ocular diseases |